本文旨在探讨旭明汤在证方记录中的作用,古代和现代关于急性脑梗死大鼠模型脑缺血损伤和血管生成的研究。SD大鼠随机分为6组:假手术组,模型组,低,medium-,高剂量(5.13、10.26和20.52g·kg~(-1),分别)徐明汤组,和丁苯酞(0.06g·kg~(-1))组。经大脑中动脉闭塞(MCAO)成功建立大鼠模型后,假手术组和模型组大鼠分别给予蒸馏水和其他组大鼠相应的药物,连续7天。神经功能评分后,所有的老鼠都被处死了,并收集脑组织样本。通过神经功能缺损评分和氯化2,3,5-三苯基四唑染色评估脑缺血损伤的程度。进行苏木精-伊红染色以观察脑的病理变化。透射电镜观察缺血侧脑组织神经元和微血管内皮细胞(ECs)的超微结构。免疫荧光法检测缺血脑组织中血管性血友病因子(vWF)和造血祖细胞抗原CD34(CD34)的表达。采用实时PCR和Westernblot检测mRNA和蛋白水平,分别,Runt相关转录因子1(RUNX1),血管内皮生长因子(VEGF),血管生成素-1(Ang-1),血管生成素-2(Ang-2),和缺血脑组织中的VEGF受体2(VEGFR2)。结果显示,与假手术组相比,模型组神经功能缺损评分和脑梗死面积增加(P<0.01),病理变化,缺血脑组织中神经元和微血管ECs的超微结构受损。此外,模型上调了RUNX1、VEGF、Ang-1,Ang-2和VEGFR2(P&lt;0.01)以及vWF的蛋白质水平,CD34,RUNX1,VEGF,Ang-1、Ang-2和VEGFR2(P<0.05或P<0.01)。与模型组相比,大剂量旭明汤和丁苯酞可降低缺血脑组织的神经功能缺损评分和脑梗死面积(P&lt;0.01),减轻缺血脑组织神经元和微血管ECs的病理改变和超微结构的损害。此外,它们上调了RUNX1,VEGF,Ang-1,Ang-2和VEGFR2(P&lt;0.01)以及vWF的蛋白质水平,CD34,RUNX1,VEGF,Ang-1、Ang-2和VEGFR2(P<0.01)。结果提示,在经证明的处方记录中,古今中外可通过调节RUNX1/VEGF通路促进MCAO大鼠缺血脑组织血管新生和侧支循环的建立,从而减轻其神经功能障碍。
This paper aims to explore the effect of Xuming Decoction in the Records of Proved Prescriptions, Ancient and Modern on cerebral ischemic injury and angiogenesis in the rat model of acute cerebral infarction. SD rats were randomized into 6 groups: sham group, model group, low-, medium-, and high-dose(5.13, 10.26, and 20.52 g·kg~(-1), respectively) Xuming Decoction groups, and butylphthalide(0.06 g·kg~(-1)) group. After the successful establishment of the rat model by middle cerebral artery occlusion(MCAO), rats in the sham and model groups were administrated with distilled water and those in other groups with corresponding drugs for 7 consecutive days. After the neurological function was scored, all the rats were sacrificed, and the brain tissue samples were collected. The degree of cerebral ischemic injury was assessed by the neurological deficit score and staining with 2,3,5-triphenyltetrazolium chloride. Hematoxylin-eosin staining was performed to observe the pathological changes in the brain. Transmission electron microscopy was employed to observe the ultrastructures of neurons and microvascular endothelial cells(ECs) on the ischemic side of the brain tissue. Immunofluorescence assay was employed to detect the expression of von Willebrand factor(vWF) and hematopoietic progenitor cell antigen CD34(CD34) in the ischemic brain tissue. Real-time PCR and Western blot were employed to determine the mRNA and protein levels, respectively, of Runt-related transcription factor 1(RUNX1), vascular endothelial growth factor(VEGF), angiopoietin-1(Ang-1), angiopoietin-2(Ang-2), and VEGF receptor 2(VEGFR2) in the ischemic brain tissue. The results showed that compared with the sham group, the model group showed increased neurological deficit score and cerebral infarction area(P<0.01), pathological changes, and damaged ultrastructure of neurons and microvascular ECs in the ischemic brain tissue. Furthermore, the modeling up-regulated the mRNA levels of RUNX1, VEGF, Ang-1, Ang-2, and VEGFR2(P<0.01) and the protein levels of vWF, CD34, RUNX1, VEGF, Ang-1, Ang-2, and VEGFR2(P<0.05 or P<0.01). Compared with the model group, high-dose Xuming Decoction and butylphthalide decreased the neurological deficit score and cerebral infarction area(P<0.01) and alleviated the pathological changes and damage of the ultrastructure of neurons and microvascular ECs in the ischemic brain tissue. Moreover, they up-regulated the mRNA levels of RUNX1, VEGF, Ang-1, Ang-2, and VEGFR2(P<0.01) and the protein levels of vWF, CD34, RUNX1, VEGF, Ang-1, Ang-2, and VEGFR2(P<0.01). The results suggest that Xuming Decoction in the Records of Proved Prescriptions, Ancient and Modern can promote the angiogenesis and collateral circulation establishment to alleviate neurological dysfunction of the ischemic brain tissue in MCAO rats by regulating the RUNX1/VEGF pathway.